Table 1.
Clinico-pathological characteristics of the Reactive Lymphoid Hyperplasia (RLH) analysed in the study
| Intensity of immunostaining | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n° | age | sex | size (cm) | Localisation | subtype | CD30 | CD15 | EBV | Versican | Fibulin-1 | Periostin |
| RLH1 | 47 | F | 0,7 | inguinal | benign lymph node | / | / | / | - | -/+ | -/+ |
| RLH2 | 68 | M | 1,3 | inguinal | benign lymph node | / | / | / | - | -/+ | + |
| RLH3 | 87 | M | 0,9 | internal mammary chain | benign lymph node | - | / | / | - | - | -/+ |
| RLH4 | 59 | M | 2 | axillary | follicular hyperplasia | +/- | - | - | - | -/+ | -/+* |
| RLH5 | 38 | M | 1,3 | cervical | follicular hyperplasia | / | / | / | - | - | -/+ |
| RLH6 | 24 | M | 1,8 | axillary | follicular hyperplasia | +/- | / | - | - | - | + |
| RLH7 | 62 | F | 0,7 | axillary | follicular hyperplasia | / | / | / | - | - | + |
| RLH8 | 22 | M | 1,2 | spinal | follicular hyperplasia | / | / | / | - | - | + |
| RLH9 | 22 | M | 1,9 | submaxillary | mixed lymphoid hyperplasia | - | - | / | - | -/+ | - |
| RLH10 | 28 | M | 1,9 | cervical | mixed lymphoid hyperplasia | / | / | - | + | -/+ | ++ |
| RLH11 | 46 | F | 1,7 | inguinal | mixed lymphoid hyperplasia | - | / | - | -/+ | -/+ | ++ |
| RLH12 | 38 | F | 1,3 | subdigastric | mixed lymphoid hyperplasia | / | / | / | - | + | ++ |
| RLH13 | 39 | F | 0,9 | supraclavicular | mixed lymphoid hyperplasia | +/- | / | / | -/+ | -/+ | ++ |
| RLH14 | 24 | F | 0,5 | cervical | sarcoidosis | / | / | / | - | -/+ | + |
| RLH15 | 57 | M | 1,5 | mediastinal | sarcoidosis | / | / | / | - | - | + |
Scoring of the intensity of the staining for fibulin-1, periostin and versican was performed as described in the "Methods" section. Cases in bold were analysed by mass spectrometry (see Additional File 2). The asterisk indicates that the protein was also detected by mass spectrometry in the same sample.